Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4481-4486

  Boehmer, Angela ^a   Anastasiadis, Aristotelis G ^a,b   Feyerabend, Susan ^a   Nagele, Udo ^a   Kuczyk, Markus ^a   Schilling, David ^a   Corvin, Stefan ^a   Merseburger, Axel S ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hormone refractory prostate cancer; Taxanes

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; FOLLOW UP; HUMAN; INFECTION; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; SKIN MANIFESTATION; STOMATITIS; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 28444486506     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ and Lowe BA: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042, 1998.
4. Petrylak DP: Chemotherapy for the treatment of hormone-refractory prostate cancer. Eur Urol Suppl 1: 15-23, 2002.
5. Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109, 1993.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
7. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S and Logothetis CJ: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157: 569-574, 1997.
8. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
9. Stein CA: Mechanisms of action of taxanes in prostate cancer. Adv Prostate Cancer 6: 3-5, 2002.
10. Oudard S, Banu E, Beuzeboc P, Dourthe LM, Vogt E, Hardy-Bessard AC, Linassier C and Vannetzel JM: Phase II randomized trial of docetaxel (D), estramustine (E) and prednisone (P) - two schedules - versus mitoxantrone (M) and prednisone (P) in patients (pts) with hormone-refractory prostate cancer (HRPC). Proc ESMO, abstr. 325, 2002.
11. Johannsen M, Wilke K, Schnorr D and Loening SA: Taxane in der Chemotherapie des hormonrefraktären Prostatakarzinoms. Urologe [A] 43: 160-167, 2004.
12. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D and Loehrer PJ: Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-2460, 1993.
13. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK and Hussain M: Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89: 431-436, 2000.
14. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckmann R, Lembersky B, Zidar B, Keating M, Reilly N and Dimitt B: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26(5 Suppl 17): 19-23, 1999.
15. Picus J and Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26(5 Suppl. 17): 14-18, 1999.
16. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ and Vogelzang NJ: Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19: 2509-2516, 2001.
17. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M and Eisenberger MA: A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients (Pts) with hormone-refractory prostate cancer (HRPC): updated preliminary analysis. Proc Am Soc Clin Oncol 19(346a): abstr. 1361, 2000.
18. Kosty MP, Ferreira A and Bryntesen T: Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc Am Soc Clin Oncol 20(152b): abstr. 2360, 2001.
19. Sitki Copur M, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L and Wendt J: Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 28: 16-21, 2001.
20. Friedland DM and Cohen JK: A phase II trial of docetaxel in hormone refractory prostate cancer. Adv Prostate Cancer 4: 5-6, 2000.
21. Berry WR, Dakhil S, Gregurich MA and Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28(4 Suppl.15): 8-15, 2001.
22. Beer TM, Pierce WC, Lowe BA and Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12: 1273-1279, 2001.
23. Bagliella B, Benson M, Diuleo R, England-Owen C, Katz A, Olsson C, Petrylak D, Pfaff C, Sawczuk I, Shelton G and Zuech N: Response and preliminary survival results of a phase II study of docetaxel (D) + estramustin (E) in patients (Pts) with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol, abstr. 1312, 2000.